| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ana Pokrajac, Andrew G Claridge, S K Abdul Shakoor, Peter J Traine. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. European journal of endocrinology. vol 154. issue 2. 2006-04-04. PMID:16452540. |
the octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. |
2006-04-04 |
2023-08-12 |
Not clear |
| B Gutt, B Steffin, J Schopoh. [Pharmacotherapy of pituitary diseases]. Der Internist. vol 46. issue 10. 2006-03-14. PMID:16133220. |
successful pharmacotherapy of pituitary hormonal excess is established only in the treatment of acromegaly (dopamine agonists, somatostatin analogues, gh-receptor-antagonists) and of prolactinomas (dopamine agonists). |
2006-03-14 |
2023-08-12 |
Not clear |
| Vera Popovi. Acromegaly - evolving strategies. Pediatric endocrinology reviews : PER. vol 1 Suppl 3. 2006-02-28. PMID:16444181. |
in optimizing the control of acromegaly new therapeutic strategies are evolving (growth hormone receptor antagonist - pegvisomant, potent dopamine agonists, universal somatostatin receptor ligands, chimeric molecules). |
2006-02-28 |
2023-08-12 |
Not clear |
| William H T Smith, R Unnikrishnan Nair, Dawn Adamson, Mark T Kearney, Stephen G Ball, Anthony J Balmfort. Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. The Journal of endocrinology. vol 187. issue 3. 2006-02-09. PMID:16423817. |
in acromegaly, somatostatin receptor ligands (srls) can ameliorate left ventricular hypertrophy (lvh) and their use is associated with demonstrable improvements in various parameters of cardiac function. |
2006-02-09 |
2023-08-12 |
human |
| Cristina L Ronchi, Virginia Varca, Paolo Beck-Peccoz, Emanuela Orsi, Francesca Donadio, Andrea Baccarelli, Claudia Giavoli, Emanuele Ferrante, Andrea Lania, Anna Spada, Maura Arosi. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. The Journal of clinical endocrinology and metabolism. vol 91. issue 1. 2006-01-31. PMID:16263816. |
comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. |
2006-01-31 |
2023-08-12 |
Not clear |
| Annamaria Colao, Roberto Attanasio, Rosario Pivonello, Paolo Cappabianca, Luigi M Cavallo, Giovanni Lasio, Alessandro Lodrini, Gaetano Lombardi, Renato Cozz. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. The Journal of clinical endocrinology and metabolism. vol 91. issue 1. 2006-01-31. PMID:16263832. |
partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. |
2006-01-31 |
2023-08-12 |
Not clear |
| Maria A Tichomirowa, Adrian F Daly, Albert Becker. Treatment of pituitary tumors: somatostatin. Endocrine. vol 28. issue 1. 2006-01-24. PMID:16311415. |
the short half-life of somatostatin makes it unsuitable for clinical use in chronic diseases, which led to the development of long-acting somatostatin analogs for the treatment of acromegaly and thyroid-stimulating hormone-secreting adenomas, which were administered by intermittent injection twice or three times a day. |
2006-01-24 |
2023-08-12 |
Not clear |
| Maria A Tichomirowa, Adrian F Daly, Albert Becker. Treatment of pituitary tumors: somatostatin. Endocrine. vol 28. issue 1. 2006-01-24. PMID:16311415. |
this review assesses the efficacy of somatostatin analogs in the treatment of pituitary adenomas, including acromegaly, thyroid-stimulating hormone-secreting tumors, non-functioning adenomas, and cushing's disease. |
2006-01-24 |
2023-08-12 |
Not clear |
| Angela N Paisley, William M Drak. Treatment of pituitary tumors: pegvisomant. Endocrine. vol 28. issue 1. 2006-01-24. PMID:16311417. |
biochemical control may be achieved with pegvisomant in patients wholly or partially resistant to somatostatin analogs, and there are emerging data to suggest that the drug may be particularly suitable for patients with acromegaly and co-existent diabetes mellitus. |
2006-01-24 |
2023-08-12 |
Not clear |
| J R Lindsay, E M McConnell, S J Hunter, D R McCance, B Sheridan, A B Atkinso. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. Pituitary. vol 7. issue 3. 2005-12-21. PMID:16328564. |
somatostatin analogues are an established treatment in acromegaly. |
2005-12-21 |
2023-08-12 |
Not clear |
| Shelly Bhayana, Gillian L Booth, Sylvia L Asa, Kalman Kovacs, Shereen Ezza. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. The Journal of clinical endocrinology and metabolism. vol 90. issue 11. 2005-12-02. PMID:16118335. |
the implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. |
2005-12-02 |
2023-08-12 |
Not clear |
| Annamaria Colao, Rosario Pivonello, Paolo Cappabianca, Francesco Briganti, Fabio Tortora, Renata S Auriemma, Maria Cristina De Martino, Paolo Marzullo, Gaetano Lombard. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clinical endocrinology. vol 63. issue 3. 2005-11-14. PMID:16117824. |
effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. |
2005-11-14 |
2023-08-12 |
Not clear |
| A Colao, R Pivonello, P Marzullo, R S Auriemma, M C De Martino, D Ferone, G Lombard. Severe systemic complications of acromegaly. Journal of endocrinological investigation. vol 28. issue 5 Suppl. 2005-11-11. PMID:16114280. |
control of acromegaly by surgery or pharmacotherapy, especially by somatostatin analogs, improves cardiovascular morbidity and sleep apnea. |
2005-11-11 |
2023-08-12 |
Not clear |
| L Forga, E Anda, J P Martínez de Esteba. [Paraneoplastic hormonal syndromes]. Anales del sistema sanitario de Navarra. vol 28. issue 2. 2005-11-07. PMID:16155618. |
in this review, we consider the following paraneoplastic hormonal syndromes: malign hypercalcaemia, hyponatraemia (inappropiate secretion of the antidiuretic hormone), ectopic cushing's syndrome, ectopic acromegaly, hypoglycaemia due to tumours different from those of the islet cells and paraneoplastic gynaecomastia; we make a brief final reference to other hormones (calcitonin, somatostatin, and vip). |
2005-11-07 |
2023-08-12 |
Not clear |
| Jens Otto Lunde Jørgensen, Ulla Feldt-Rasmussen, Jan Frystyk, Jian-Wen Chen, Lars Østergård Kristensen, Claus Hagen, Hans Ørsko. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. The Journal of clinical endocrinology and metabolism. vol 90. issue 10. 2005-11-02. PMID:16046586. |
cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. |
2005-11-02 |
2023-08-12 |
Not clear |
| Ariel L Barkan, Pia Burman, David R Clemmons, William M Drake, Robert F Gagel, Philip E Harris, Peter J Trainer, Aart Jan van der Lely, Mary Lee Vanc. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. The Journal of clinical endocrinology and metabolism. vol 90. issue 10. 2005-11-02. PMID:16076947. |
in clinical practice, patients with acromegaly may be switched from therapy with long-acting somatostatin analogs to pegvisomant. |
2005-11-02 |
2023-08-12 |
Not clear |
| Raquel S Jallad, Nina R C Musolino, Luiz R Salgado, Marcello D Bronstei. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clinical endocrinology. vol 63. issue 2. 2005-11-01. PMID:16060910. |
somatostatin analogues have become the mainstay of the medical treatment of acromegaly. |
2005-11-01 |
2023-08-12 |
Not clear |
| Joseph M Cendros, Concepción Peraire, Iñaki Fernández Trocóniz, Rossend Obac. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism: clinical and experimental. vol 54. issue 10. 2005-10-27. PMID:16154424. |
somatostatin analogs are the first-line medical therapy for acromegaly, and the treatment of this disease has been simplified by the development of extended-release formulations of these analogs. |
2005-10-27 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Alberto M Pereira, Jan W A Smit, Johannes A Romijn, Ferdinand Roelfsem. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 15. issue 3. 2005-10-11. PMID:15935982. |
depot formulations of somatostatin analogues are increasingly used in the treatment of active acromegaly. |
2005-10-11 |
2023-08-12 |
Not clear |
| A Atmaca, T Erba. Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 113. issue 6. 2005-10-04. PMID:15977102. |
octreotide is the first somatostatin analogue to become available for clinical use in the treatment of acromegaly. |
2005-10-04 |
2023-08-12 |
Not clear |